
 <font color='red' size='5'>  Problems and objectives </font> 

<font color='black' size='3'>

1. 70% of breast cancer patients are ER+ treated by Tamoxifen.
2. However 50% of them developed resistance 
3. Mechanism of resistance still unknown 
4. To find novel FDA approved molecules that overcome tamoxifen resistance. 


![Image of Block Diagram](http://fadhl-alakwa.weebly.com/uploads/5/3/6/4/5364958/overview_orig.png)

 <font color='red' size='5'>  methods </font> 
 
 Integrate gene expression data, pathways, drug biobank and CLUE.io

 <font color='red' size='5'>  results </font> 
 
We found a drug that can be prescribed with tamoxifen for patients who developed resistance to tamoxifen.

1. This drug beats the currently available drug. 
2. There is no any claims about this drug either in the market or the literature that show it mediate  tamoxifen resistance. 
3. This drug bring up a new combination of target genes (gene A and gene B) to overcome tamoxifen resistance.
4. There is no toxicity of the drug on the normal cell line.




![Image of Block Diagram](http://fadhl-alakwa.weebly.com/uploads/5/3/6/4/5364958/list_orig.png)

![Image of Block Diagram](http://fadhl-alakwa.weebly.com/uploads/5/3/6/4/5364958/invitro_orig.png)
